BioLargo enters $10M equity purchase agreement with Clearthink Capital Partners

BIOLARGO, INC.

Clearthink commits to buy up to $10M of BioLargo common stock over 36 months under a Strata purchase agreement.
Draws limited to $500K per notice; pricing equals avg of two lowest closing prices in prior 8 trading days; min $25K.
BioLargo issued 500,000 commitment shares to Clearthink as consideration; no cash proceeds from those shares.
Clearthink prohibited from short selling or hedging during term; beneficial ownership capped at 9.99%.
Proceeds to be used for working capital and general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BIOLARGO, INC. entered into Purchase Agreement with CLEARTHINK CAPITAL PARTNERS, LLC valued at up to $10.0 million (effective 2026-03-20).

Action: entry
Agreement: equity purchase
Counterparty: CLEARTHINK CAPITAL PARTNERS, LLC
Value: up to $10.0 million
Effective: 2026-03-20

Exact text from the filing

On March 20, 2026, BioLargo, Inc. (the “Company” or “we”) entered into a purchase agreement dated as of March 20, 2026 (the “Purchase Agreement”), and a registration rights agreement dated as of March 20, 2026 (the “Registration Rights Agreement”), with CLEARTHINK CAPITAL PARTNERS, LLC (“Clearthink”), pursuant to which Clearthink has committed to purchase up to $10.0 million of the Company’s common stock

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

BIOLARGO, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-009813

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.